Gate Bioscience is a technology company.
Gate Bioscience has raised $125.0M across 2 funding rounds.
Gate Bioscience has raised $125.0M in total across 2 funding rounds.
Gate Bioscience has raised $125.0M in total across 2 funding rounds.
Gate Bioscience's investors include Andreessen Horowitz, ARCH Venture Partners, Scott Biller, Versant Ventures, GV, Mohamad Makhzoumi, Westlake Village BioPartners.
Gate Bioscience is a preclinical-stage biotechnology company developing Molecular Gates, a novel class of small molecule therapeutics that selectively block and eliminate disease-causing extracellular proteins at their source inside cells, preventing secretion.[1][2][3][7] These oral drugs target the secretory translocon—a cellular channel essential for protein secretion—and address proteins implicated in cancer, neurodegeneration, fibrosis, inflammatory, and neurological diseases, including prion protein (PrP).[1][3][4] Founded in 2021 and headquartered in Brisbane, California, the company has raised $60M in Series A (2023) and an oversubscribed $65M Series B, serving the healthcare and pharmaceutical industries with a platform enabling rapid discovery against high-value targets.[1][2][3] Gate serves patients with unmet needs in these areas, solving the challenge of targeting "undruggable" extracellular proteins that biologics struggle to address due to poor oral bioavailability and blood-brain barrier penetration.[1][3][5]
Gate Bioscience was founded in 2021 by Jordi Mata-Fink, Ph.D. (Co-founder and CEO), emerging from stealth with a $60M Series A led by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV.[1][2][5] The idea stems from expertise in protein secretion mechanics, particularly the secretory translocon (e.g., Sec61), driven by scientific founders and advisors like Pat Sharp, Rebecca Voorhees, Ramanujan Hegde, and Ville Paavilainen.[1] Early traction included building the Molecular Gate Discovery Platform, which integrates a privileged compound library, secretion assays, and secretory pathway biology know-how.[3][7] Pivotal moments feature the 2023 public launch, a Lilly collaboration and license agreement for novel molecular gates (with upfront payment, equity, milestones, and royalties), a Series B raise, and appointing biotech veteran Jeff Hatfield to the board in August 2024.[2][3][5]
Gate Bioscience rides the trend of targeted protein degradation and secretion modulation, expanding beyond intracellular PROTACs to extracellular proteins via the translocon, amid rising demand for oral alternatives to injectables in immunology, neurology, and rare diseases like prion disorders.[1][3][4] Timing aligns with advances in translocon biology and AI-driven drug discovery, unlocking >1,000 disease-linked proteins; market forces favor small molecules for their scalability, cost, and CNS access in a biologics-dominated field.[1][3] Gate influences the ecosystem through its platform's modularity—potentially disrupting treatments for fibrosis, cancer, and neurodegeneration—and partnerships like Lilly, accelerating clinical translation and validating the modality for broader adoption.[5]
Gate Bioscience is poised to advance its lead programs into the clinic post-Series B, with the Lilly collaboration likely yielding first proof-of-concept data in inflammatory or neurological targets within 2-3 years.[3][5] Trends like oral CNS drugs and secretion-targeted therapies will propel growth, especially if PrP-lowering succeeds for prion disease prevention.[4] Influence may evolve via expanded partnerships, additional financings, or platform licensing, positioning Gate as a leader in redefining protein elimination—transforming "Molecular Gates" from preclinical promise to a new therapeutic category that outpaces biologics in accessibility and impact.[1][3]
Gate Bioscience has raised $125.0M across 2 funding rounds. Most recently, it raised $65.0M Series B in November 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2025 | $65.0M Series B | Andreessen Horowitz, ARCH Venture Partners, Scott Biller, Versant Ventures | |
| Oct 1, 2023 | $60.0M Series A | Andreessen Horowitz, ARCH Venture Partners, Scott Biller, GV, Mohamad Makhzoumi, Versant Ventures, Westlake Village BioPartners |